Bile Pigments in Pulmonary and Vascular Disease

The bile pigments, biliverdin, and bilirubin, are endogenously derived substances generated during enzymatic heme degradation. These compounds have been shown to act as chemical antioxidants in vitro. Bilirubin formed in tissues circulates in the serum, prior to undergoing hepatic conjugation and biliary excretion. The excess production of bilirubin has been associated with neurotoxicity, in particular to the newborn. Nevertheless, clinical evidence suggests that mild states of hyperbilirubinemia may be beneficial in protecting against cardiovascular disease in adults. Pharmacological application of either bilirubin and/or its biological precursor biliverdin, can provide therapeutic benefit in several animal models of cardiovascular and pulmonary disease. Furthermore, biliverdin and bilirubin can confer protection against ischemia/reperfusion injury and graft rejection secondary to organ transplantation in animal models. Several possible mechanisms for these effects have been proposed, including direct antioxidant and scavenging effects, and modulation of signaling pathways regulating inflammation, apoptosis, cell proliferation, and immune responses. The practicality and therapeutic-effectiveness of bile pigment application to humans remains unclear.

[1]  B. Croker,et al.  Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. , 2005, American journal of physiology. Renal physiology.

[2]  A. Kaliora,et al.  Dietary antioxidants in preventing atherogenesis. , 2006, Atherosclerosis.

[3]  M. N. Hughes,et al.  Interaction of bilirubin and biliverdin with reactive nitrogen species , 2003, FEBS letters.

[4]  T. Church,et al.  Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. , 2011, The American journal of cardiology.

[5]  M. Moore Characterization of the enzyme , 1994 .

[6]  Xueying Sun,et al.  Bilirubin protects grafts against nonspecific inflammation-induced injury in syngeneic intraportal islet transplantation , 2010, Experimental & Molecular Medicine.

[7]  H. Schwertner,et al.  Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. , 2008, Atherosclerosis.

[8]  F. Bach,et al.  Bilirubin can induce tolerance to islet allografts. , 2006, Endocrinology.

[9]  M. Gulley,et al.  UGT1A1 Promoter Genotype is not Strongly Associated With Severity of Coronary Artery Disease , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[10]  J. Keaney,et al.  Reactive oxygen species in cardiovascular disease. , 2011, Free radical biology & medicine.

[11]  S. Koh,et al.  Inverse association between total bilirubin and metabolic syndrome in rural korean women. , 2011, Journal of women's health.

[12]  R. Stocker,et al.  Synergistic interaction between vitamin E and the bile pigments bilirubin and biliverdin. , 1989, Biochimica et biophysica acta.

[13]  D. Keppler,et al.  Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6* , 2001, The Journal of Biological Chemistry.

[14]  J. Kastelein,et al.  Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease? , 2011, Journal of Lipid Research.

[15]  W. Dröge Free radicals in the physiological control of cell function. , 2002, Physiological reviews.

[16]  H. Hashimoto,et al.  High serum bilirubin level is inversely associated with the presence of carotid plaque. , 2001, Stroke.

[17]  Y. Hecht [Bilirubin metabolism and its disorders]. , 1971, Revue medico-chirurgicale des maladies du foie.

[18]  G. Kikuchi,et al.  Specific requirement of NADPH‐cytochrome c reductase for the microsomal heme oxygenase reaction yielding biliverdin IXα , 1979, FEBS letters.

[19]  R. Stocker,et al.  Limited Role for the Bilirubin-Biliverdin Redox Amplification Cycle in the Cellular Antioxidant Protection by Biliverdin Reductase* , 2009, The Journal of Biological Chemistry.

[20]  F. Iber,et al.  Hepatology: A Textbook of Liver Disease , 1983 .

[21]  R. Takayanagi,et al.  Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. , 2010, Kidney international.

[22]  R. Foresti,et al.  Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. , 2004, Biochemical Society symposium.

[23]  L. Novotný,et al.  Inverse Relationship Between Serum Bilirubin and Atherosclerosis in Men: A Meta-Analysis of Published Studies , 2003, Experimental biology and medicine.

[24]  R. Stocker,et al.  Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. , 1994, The Journal of biological chemistry.

[25]  Florian Kronenberg,et al.  Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study , 2006, Circulation.

[26]  M. Maines,et al.  Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. , 2009, Trends in pharmacological sciences.

[27]  N. Nakamura,et al.  Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. , 2008, Kidney international.

[28]  S. Jee,et al.  Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population , 2011, Endocrine.

[29]  A. O. Pedersen,et al.  Photooxidation of human serum albumin and its complex with bilirubin. , 1977, European journal of biochemistry.

[30]  G. Kikuchi,et al.  Sequence of the reaction of heme catabolism catalyzed by the microsomal heme oxygenase system , 1974, FEBS letters.

[31]  N. Chowdhury,et al.  Purification and partial characterization of rat liver bilirubin glucuronoside glucuronosyltransferase. , 1979, The Journal of biological chemistry.

[32]  Z. Mareček,et al.  Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. , 2002, Atherosclerosis.

[33]  H. Kesteloot,et al.  Serum bilirubin and 10-year mortality risk in a Belgian population , 2001, Cancer Causes & Control.

[34]  S. Ryter,et al.  Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. , 2007, American journal of respiratory cell and molecular biology.

[35]  F. Liu,et al.  Biliverdin administration protects against endotoxin-induced acute lung injury in rats. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[36]  H. Marver,et al.  Microsomal heme oxygenase. Characterization of the enzyme. , 1969, The Journal of biological chemistry.

[37]  G. Carter’George,et al.  Is Bilirubin Protective Against Coronary Artery Disease ? , 2022 .

[38]  A. Bulmer,et al.  Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. , 2008, Atherosclerosis.

[39]  P. Sarathchandra,et al.  Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. , 2000, American journal of physiology. Heart and circulatory physiology.

[40]  J. Weuve,et al.  Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. , 2008, The American journal of medicine.

[41]  N. Nakamura,et al.  Low serum bilirubin concentration in haemodialysis patients with Type 2 diabetes , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[42]  G. Kikuchi,et al.  Oxygenated form of heme . heme oxygenase complex and requirement for second electron to initiate heme degradation from the oxygenated complex. , 1980, The Journal of biological chemistry.

[43]  Hidetada Sasaki,et al.  Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. , 2002, American journal of respiratory and critical care medicine.

[44]  D. Stolz,et al.  Protection Against Ischemia/Reperfusion Injury in Cardiac and Renal Transplantation with Carbon Monoxide, Biliverdin and Both , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[45]  Chien Ho,et al.  Biliverdin Administration Prevents the Formation of Intimal Hyperplasia Induced by Vascular Injury , 2005, Circulation.

[46]  Sang-Hwan Kim,et al.  Relationship between bilirubin and C-reactive protein , 2011, Clinical chemistry and laboratory medicine.

[47]  F. Kronenberg,et al.  Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. , 2008, Clinical chemistry.

[48]  S. Ebrahim,et al.  Serum bilirubin and risk of ischemic heart disease in middle-aged British men. , 1995, Clinical chemistry.

[49]  H. Forman,et al.  Signaling functions of reactive oxygen species. , 2010, Biochemistry.

[50]  J. Chan,et al.  Serum Bilirubin and Cardiovascular Risk Factors in a Chinese Population , 1996, Journal of cardiovascular risk.

[51]  H. Schwertner,et al.  Association of low serum concentration of bilirubin with increased risk of coronary artery disease. , 1994, Clinical chemistry.

[52]  L. Rodella,et al.  Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. , 2006, Free radical biology & medicine.

[53]  J. Ghersi-Egea,et al.  Blood-brain interfaces and bilirubin-induced neurological diseases. , 2009, Current pharmaceutical design.

[54]  S. Snyder,et al.  Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[55]  E. Yıldırım,et al.  Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. , 2006, Atherosclerosis.

[56]  J. Ostrow,et al.  Bilirubin chemistry and metabolism; harmful and protective aspects. , 2009, Current pharmaceutical design.

[57]  R. Stocker,et al.  Bilirubin attenuates radical‐mediated damage to serum albumin , 1993, FEBS letters.

[58]  D. Levy,et al.  Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. , 2001, The American journal of cardiology.

[59]  C. Mancuso,et al.  Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide. , 2003, Biochemical pharmacology.

[60]  F. Kronenberg,et al.  Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels--the Framingham Heart Study. , 2009, Atherosclerosis.

[61]  Z. Mareček,et al.  Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels , 1998 .

[62]  A. Froio,et al.  Bilirubin: A Natural Inhibitor of Vascular Smooth Muscle Cell Proliferation , 2005, Circulation.

[63]  H. Marver,et al.  Reduced nicotinamide-adenine dinucleotide phosphate dependent biliverdin reductase: partial purification and characterization. , 1970, Biochemistry.

[64]  R. Mccauley,et al.  Glutathione , 2003, Reactions Weekly.

[65]  D. Stevenson,et al.  Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. , 1995, Free radical biology & medicine.

[66]  G. Lippi,et al.  Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? , 2010, Advances in clinical chemistry.

[67]  E. Gabazza,et al.  Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance , 2000, Journal of Gastroenterology.

[68]  B. Ames,et al.  Bilirubin is an antioxidant of possible physiological importance. , 1987, Science.

[69]  F. Kronenberg,et al.  Association Between the UGT 1 A 1 * 28 Allele , Bilirubin Levels , and Coronary Heart Disease in the Framingham Heart Study , 2006 .

[70]  T. Sedlak,et al.  Cycling the Wagons for Biliverdin Reductase , 2009, The Journal of Biological Chemistry.

[71]  M. Valko,et al.  Free radicals, metals and antioxidants in oxidative stress-induced cancer. , 2006, Chemico-biological interactions.

[72]  D. Gemsa MICROSOMAL HEME OXYGENASE , 1981 .

[73]  J. Ostrow,et al.  Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. , 2009, Biochemical and biophysical research communications.

[74]  S. Hunt,et al.  Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[75]  Solomon H. Snyder,et al.  Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[76]  V. Gorrepati,et al.  High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999 - 2006 , 2010, Journal of clinical medicine research.

[77]  B. Ketterer,et al.  Ligandin: a Hepatic Protein which Binds Steroids, Bilirubin, Carcinogens and a Number of Exogenous Organic Anions , 1971, Nature.

[78]  M. Maines,et al.  The heme oxygenase system: a regulator of second messenger gases. , 1997, Annual review of pharmacology and toxicology.

[79]  M. Erbil,et al.  Decreased small dense LDL levels in Gilbert's syndrome. , 2011, Clinical biochemistry.

[80]  N. Chowdhury,et al.  Bilirubin metabolism: Applied physiology , 2006 .

[81]  F. Bach,et al.  Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  M. Maines,et al.  Small Interference RNA-mediated Gene Silencing of Human Biliverdin Reductase, but Not That of Heme Oxygenase-1, Attenuates Arsenite-mediated Induction of the Oxygenase and Increases Apoptosis in 293A Kidney Cells* , 2005, Journal of Biological Chemistry.

[83]  R. Foresti,et al.  Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. , 2000, The Biochemical journal.

[84]  R. Stocker,et al.  Reply to Sedlak and Snyder: The Little Bighorn of the Biliverdin Reductase Amplification Cycle , 2009, The Journal of Biological Chemistry.

[85]  C. Harris,et al.  Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase , 2011, Proceedings of the National Academy of Sciences.

[86]  J. Beckman,et al.  Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004 , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[87]  A. García-Lafuente,et al.  Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease , 2009, Inflammation Research.

[88]  H. Gullu,et al.  High Serum Bilirubin Concentrations Preserve Coronary Flow Reserve and Coronary Microvascular Functions , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[89]  K. Walters,et al.  Serum bilirubin and risk of respiratory disease and death. , 2011, JAMA.

[90]  H. Ichiki,et al.  Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. , 2011, Journal of atherosclerosis and thrombosis.

[91]  B. Ames,et al.  Potential role of conjugated bilirubin and copper in the metabolism of lipid peroxides in bile. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[92]  R. Stocker,et al.  Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. , 1989, Free radical research communications.

[93]  B. Stevens,et al.  THE PHOTOPEROXIDATION OF UNSATURATED ORGANIC MOLECULES—XV. O2 1 δg QUENCHING BY BILIRUBIN AND BILIVERDIN , 1976, Photochemistry and photobiology.

[94]  Daling Zhu,et al.  Protection against lung graft injury from brain-dead donors with carbon monoxide, biliverdin, or both. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[95]  S. Gustincich,et al.  Redox state, oxidative stress, and molecular mechanisms of protective and toxic effects of bilirubin on cells. , 2009, Current pharmaceutical design.

[96]  F. Bach,et al.  Biliverdin therapy protects rat livers from ischemia and reperfusion injury , 2004, Hepatology.

[97]  Wenda Gao,et al.  Heme oxygenase‐1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[98]  N. Chowdhury,et al.  Conjugation and Excretion of Bilirubin , 1983, Seminars in liver disease.

[99]  D. Levy,et al.  Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). , 2003, The American journal of cardiology.

[100]  B. Ames,et al.  Antioxidant activity of albumin-bound bilirubin. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. S. Levinson Relationship between bilirubin, apolipoprotein B, and coronary artery disease. , 1997, Annals of clinical and laboratory science.

[102]  Rui F. M. Silva,et al.  Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. , 2008, Neurotoxicology.

[103]  F. Bach,et al.  Therapeutic applications of bilirubin and biliverdin in transplantation. , 2007, Antioxidants & redox signaling.

[104]  K. Davies Oxidative Stress, Antioxidant Defenses, and Damage Removal, Repair, and Replacement Systems , 2000, IUBMB life.

[105]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[106]  N. Abraham,et al.  Heme oxygenase -1 gene therapy: recent advances and therapeutic applications. , 2007, Current gene therapy.

[107]  K. Davies Oxidative stress: the paradox of aerobic life. , 1995, Biochemical Society symposium.